uniQure NV (NAS:QURE)
$ 5.495 0.165 (3.1%) Market Cap: 266.78 Mil Enterprise Value: -158.60 Mil PE Ratio: 0 PB Ratio: 1.81 GF Score: 48/100

Uniqure NV at Chardan Genetic Medicines Conference Transcript

Oct 03, 2022 / 12:30PM GMT
Release Date Price: $19.53 (+4.10%)
Unidentified Analyst

Next session, allow me to introduce our guests, Ricardo Dolmetsch, President of Research and Development at uniQure. Ricardo, it's a pleasure to have you with us.

Ricardo Dolmetsch
uniQure N.V. - President, Research & Development

Thank you. Thanks for the invitation.

Questions & Answers

Unidentified Analyst

So to get started, do you mind giving us some introductory comments on uniQure? What the company is about and the general strategy the company is using to combat disease?

Ricardo Dolmetsch
uniQure N.V. - President, Research & Development

Yes. So we're a gene therapy company focused on diseases of the liver and the central nervous system. We have been working on this for more than 20 years. We registered the first gene therapy in the West, which was Glybera. And we now have a pipeline in hemophilia, in Huntington's disease, in Fabry, in temporal lobe epilepsy.

And we are also GMP manufacturers of AAV gene therapies. We have -- we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot